November 5, 2020
Guardant Health Reports Third Quarter 2020 Financial Results
Q3 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading…
Pharmaceuticals, Biotechnology and Life Sciences
Q3 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading…
– U.S. QINLOCK® Net Revenue of $14.7 Million in the First Full Quarter of Launch – – Marketing Authorisation Application…
Presented Initial Clinical Data from Phase 1 Study of SY-5609 at EORTC-NCI-AACR Conference New Clinical and Translational Data for SY-1425…
October Financing Raised $75.2 Million in Proceeds Net of Fees DEXTENZA® Net Product Revenue in Third Quarter of $5.4 Million,…
— Management to Host Conference Call at 4:30 p.m. EST Today — MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical…
FDA grants two Orphan Drug Designations to KZR-616 for the treatment of Dermatomyositis (DM) and Polymyositis (PM) KZR-616 clinical and…
Year-to-Date Net Revenues of $58.5 Million Increased 29% over 2019 Third Quarter Net Revenues of $20.1 Million or $77 Per…
Signs Letter of Intent with Felix Biotechnology to license Thin Film Freezing technology for their bacteriophage products for lung inhalation…
Felix Biotechnology would obtain worldwide license for Thin Film Freezing technology to develop a novel, bacteriophage-based biotherapeutic Proposed terms provide…
Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR), a global oncology company striving…